Guest Post by David Kliff, Editor, Diabetic Investor

As I left Vienna after attending the 11th International Conference on Advanced Technologies & Treatments for Diabetes, my thoughts turned to what does this all mean, what was the most significant takeaway? By far the most significant development coming out of ATTD is the long quest to have a REAL closed-loop insulin delivery system is no longer a pipe dream. This is going to happen and for once I believe it will happen in my lifetime. It is difficult to overstate the power of the data I witnessed. The reality here is that some very smart people have come a very long way.

According to a recent study, which one of the following diabetes therapies carries a lower risk for adverse cardiovascular (CV) events? 1. Nonspecific, long-acting sulfonylureas (eg, glyburide and glimepiride) 2. Specific, short-acting sulfonylureas (eg, glipizide, tolbutamide) 3. CV risk does not differ between these agents Follow the link for the answer.

Do you provide any kind of exercise program for your patients? Follow the link to see how you compare to your colleagues.

Dr. Jim McDermott is Vice President of US Medical Affairs for Diabetes at AstraZeneca. He has been with AstraZeneca for more than two decades.

This Exclusive Interview transcript allows you to read the full conversation between Dr. Jim McDermott and Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA. Dr. McDermott discusses the SGLT-2 research at AstraZeneca, including the CVD-REAL  large outcomes trial.

In this Exclusive Interview, Dr. Jim McDermott talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about AstraZeneca SGLT-2 research, including the CVD-REAL  large outcomes trial.

In part 1 of this Exclusive Interview, Dr. Jim McDermott explains the recent AstraZeneca SGLT2 trials in a conversation with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA.

In part 2 of this Exclusive Interview, Dr. Jim McDermott explains what research shows about the the efficacy of SGLT2 inhibitors and their benefit to risk ratio in a conversation with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA.

In part 3 of this Exclusive Interview, Dr. Jim McDermott explains the DURATION-8 study of Bydureon and dapagliflozin combo therapy in a conversation with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA.

In part 4 of this Exclusive Interview, Dr. Jim McDermott discusses patient response to the DURATION-8 study, and the continuation of the study in 2018, in a conversation with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA.